NGC Update Service: August 5, 2013

August 5, 2013 New This Week Guideline Synthesis Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease (COPD) Update: Includes revised recommendations from GOLD Guideline Summaries American College of Radiology ACR Appropriateness Criteria® clinically suspected adnexal mass. This updates a previously published guideline summary. ACR Appropriateness Criteria® prostate cancer—pretreatment detection, staging and surveillance. This updates a previously published guideline summary. ACR Appropriateness Criteria® renal transplant dysfunction. This updates a previously published guideline summary. ACR Appropriateness Criteria® renal trauma. American Society of Clinical Oncology Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. This updates a previously published guideline summary. Eastern Association for the Surgery of Trauma An evidence-based review: helmet efficacy to reduce head injury and mortality in motorcycle crashes: EAST practice management guidelines. This updates a previously published guideline summary. Eastern Association for the Surgery of Trauma practice management guidelines for hemorrhage in pelvic fracture—update and systematic review. This updates a previously published guideline summary. Evaluation and management of mild traumatic brain injury: an Eastern Association for the Surgery of Trauma practice management guideline. This updates a previously published guideline summary. Evaluation and management of penetrating lower extremity arterial trauma: an Eastern Association for the Surgery of Trauma practice management guideline. This updates a previously published guideline summary. Evaluation and management of small-bowel obstruction: an Eastern Association for the Surgery of Trauma practice management guideline. Management of pulmonary contusion and flail chest: an Eastern Association for the Surgery of Trauma practice management guideline. This updates a previously published guideline summary. Announcements New Search Tutorial View the new Search Video to learn more about the search and browse features on the NGC Web site. Revised Inclusion Criteria NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments. Health Awareness Topics - August 2013 National Breastfeeding Month (see related guidelines) National Immunization Awareness Month (see related guidelines) Psoriasis Awareness Month (see related guidelines) Conference News The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site. U.S. Food and Drug Administration (FDA) Advisories August 1, 2013: Acetaminophen: FDA notified healthcare professionals and patients that acetaminophen has been associated with a risk of rare but serious skin reactions. Acetaminophen is a common active ingredient to treat pain and reduce fever; it is included in many prescription and over-the-counter (OTC) products. These skin reactions, known as Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP), can be fatal. These reactions can occur with first-time use of acetaminophen or at any time while it is being taken. July 29, 2013: Mefloquine Hydrochloride: FDA is advising the public about strengthened and updated warnings regarding neurologic and psychiatric side effects associated with the antimalarial drug mefloquine hydrochloride. A boxed warning has been added to the drug label. FDA has revised the patient Medication Guide dispensed with each prescription and wallet card to include this information and the possibility that the neurologic side effects may persist or become permanent. The neurologic side effects can include dizziness, loss of balance, or ringing in the ears. The psychiatric side effects can include feeling anxious, mistrustful, depressed, or having hallucinations. July 26, 2013: Nizoral (ketoconazole): FDA is taking several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug's use, warning that it can cause severe liver injuries and adrenal gland problems, and advising that it can lead to harmful drug interactions with other medications. FDA has approved label changes and added a new Medication Guide to address these safety issues. As a result, Nizoral oral tablets should not be a first-line treatment for any fungal infection. Nizoral should be used for the treatment of certain fungal infections, known as endemic mycoses, only when alternative antifungal therapies are not available or tolerated. NGC's Sister Resources Find Innovations and QualityTools classified by disease or clinical category, patient population, setting of care, stage of care, and more in AHRQ's Health Care Innovations Exchange Web site. Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).    How satisfied are you with this e-mail bulletin? Give Us Your Feedback Subscriber Services: Change Your Profile | Unsubscribe | Help Stay Connected: Contact Us | Social Media This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364